Literature DB >> 11563047

2-substituted pi system derivatives of adenosine that are coronary vasodilators acting via the A2A adenosine receptor.

J Zablocki1, V Palle, B Blackburn, E Elzein, G Nudelman, S Gothe, Z Gao, Z Li, S Meyer, L Belardinelli.   

Abstract

Compound 20 (CVT-3146--a 2-[(N-1-(4-N-methylcarboxamidopyrazolyl)] adenosine derivative) and compound 31 (CVT-3033--a 2-[(4-(1-N-pentylpyrazolyl)] adenosine derivative), were found to be short acting functionally selective coronary vasodilators (CV t0.5 = 5.2 +/- 0.2 and 3.4 +/- 0.5 min, respectively--rat isolated heart 50% reversal time) with good potency (EC50S = 6.4 +/- 1.2 nM and 67.9 +/- 16.7 nM, respectively), but they possess low affinity for the ADO A2A receptor (Ki = 1122 +/- 323 nM and 2138 +/- 952 nM, respectively; pig striatum).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11563047     DOI: 10.1081/NCN-100002306

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  5 in total

1.  Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor.

Authors:  Francesca Deflorian; T Santhosh Kumar; Khai Phan; Zhan-Guo Gao; Fei Xu; Huixian Wu; Vsevolod Katritch; Raymond C Stevens; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2011-12-12       Impact factor: 7.446

2.  Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: rationale and design of a prospective, randomized, multicenter study.

Authors:  Furqan H Tejani; Randall C Thompson; Ami E Iskandrian; Bruce E McNutt; Billy Franks
Journal:  J Nucl Cardiol       Date:  2010-11-17       Impact factor: 5.952

3.  Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position.

Authors:  Michihiro Ohno; Zhan-Guo Gao; Philippe Van Rompaey; Susanna Tchilibon; Soo-Kyung Kim; Brian A Harris; Ariel S Gross; Heng T Duong; Serge Van Calenbergh; Kenneth A Jacobson
Journal:  Bioorg Med Chem       Date:  2004-06-01       Impact factor: 3.641

4.  A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease.

Authors:  Karthik Ananthasubramaniam; Robert Weiss; Bruce McNutt; Barbara Klauke; Kathleen Feaheny; Stan Bukofzer
Journal:  J Nucl Cardiol       Date:  2012-01-19       Impact factor: 5.952

Review 5.  Regadenoson in the detection of coronary artery disease.

Authors:  Christiane Buhr; Mario Gössl; Raimund Erbel; Holger Eggebrecht
Journal:  Vasc Health Risk Manag       Date:  2008
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.